albuterol sulfate; budesonide - Profile

What are the generic sources for albuterol sulfate; budesonide and what is the scope of freedom to operate?

Albuterol sulfate; budesonide is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Albuterol sulfate; budesonide has one hundred and ninety-two patent family members in thirty-two countries.

Summary for albuterol sulfate; budesonide

International Patents:	192
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for albuterol sulfate; budesonide

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for albuterol sulfate; budesonide

Constraining patent/regulatory exclusivity:

LABELING REVISIONS TO REFLECT THE RESULTS OF BATURA STUDY

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for albuterol sulfate; budesonide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	AIRSUPRA	albuterol sulfate; budesonide	AEROSOL, METERED;INHALATION	214070-001	Jan 10, 2023		RX	Yes	Yes	9,415,009
Astrazeneca	AIRSUPRA	albuterol sulfate; budesonide	AEROSOL, METERED;INHALATION	214070-001	Jan 10, 2023		RX	Yes	Yes
Astrazeneca	AIRSUPRA	albuterol sulfate; budesonide	AEROSOL, METERED;INHALATION	214070-001	Jan 10, 2023		RX	Yes	Yes

International Patents for albuterol sulfate; budesonide

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010138862
Hungary	E029532
Japan	2017222706
Japan	6348645
Taiwan	I539979
Lithuania	C2435024

Supplementary Protection Certificates for albuterol sulfate; budesonide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	2190014-7	Sweden		PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
2435025	1990034-9	Sweden		PRODUCT NAME: A COMBINATION OF GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALT OR ESTERS THEREOF AND FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS THEREOF.; REG. NO/DATE: EU/1/18/1339 20181220
2435025	CR 2019 00032	Denmark		PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER SOLVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220
2435024	C02435024/01	Switzerland		PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021
2435024	C202130025	Spain		PRODUCT NAME: UNA COMBINACION DE FORMOTEROL ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES I, GLICOPIRROLATO ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES ) Y BUDESONIDA ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES ).; NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF AUTHORISATION: 20201209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1498; DATE OF FIRST AUTHORISATION IN EEA: 20201209
2435024	CA 2021 00014	Denmark		PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210

Investment Scenario, Market Dynamics, and Financial Trajectory for Albuterol Sulfate and Budesonide

Last updated: February 3, 2026

Executive Summary

This analysis evaluates the current and projected market landscape for two key respiratory drugs: Albuterol Sulfate and Budesonide. Both have established roles in asthma and COPD management, but evolving market trends, policy changes, patent statuses, and competitive dynamics influence their investment viability and growth potential.

Key highlights:

• Market Size & Growth: The combined global respiratory drug market was valued at approximately $17.4 billion in 2022, with an expected CAGR of 4.8% (2023-2030).
• Product Lifecycle: Patents for many branded formulations are nearing expiry or have expired, encouraging generic proliferation.
• R&D & Innovation: Increased investments in inhaler delivery technologies and biosimilars may impact market shares.
• Regulatory and Policy Factors: Increasing emphasis on inhaler device sustainability and cost-effectiveness influences market dynamics.
• Market Drivers: Rising prevalence of respiratory diseases, especially COPD and asthma, sustained by aging populations and environmental factors.
• Challenges: Patent expirations, reimbursement policies, and competitive pressures from generics and novel therapies.

---

What Are Albuterol Sulfate and Budesonide?

Drug	Active Ingredient	Therapeutic Class	Formulation	Primary Uses
Albuterol Sulfate	Albuterol	Short-acting beta-agonist (SABA)	Inhaler (MDI and DPI), nebulizer solutions	Relief of acute bronchospasm in asthma & COPD
Budesonide	Budesonide	Inhaled corticosteroid (ICS)	Dry powder inhaler (DPI), nebulizer solutions	Long-term control of asthma & COPD

---

Market Size and Growth Dynamics

Global Market Overview (2022-2030)

Parameter	2022	2025 (Forecast)	2030 (Forecast)	CAGR (2023-2030)	Notes
Market Value ($ billion)	17.4	22.0	27.4	4.8%	Source: Grand View Research[1]
Target Indication	Asthma, COPD	Same	Same	N/A
Key Regions	North America 45%, Europe 30%, Asia-Pacific 15%, Rest of World 10%	Same	Same	N/A

Market Segmentation

Drug Category	Value ($ billion, 2022)	Share (%)	Projected 2030 Share (%)	Comments
Albuterol	$4.5	25.9%	22%	Dominant in acute relief inhalers; patent expirations impact this segment
Budesonide	$3.8	21.8%	26%	Long-term maintenance therapy in asthma and COPD; strong generic presence
Combination Therapies	$4.5	25.9%	27%	Increasing uptake, integrating ICS and LABA (Long-acting beta-agonists)

---

Market Drivers

Epidemiology and Demographics

• Rising prevalence of asthma and COPD globally. The WHO estimates that over 340 million people suffer from asthma, and COPD causes 3 million deaths annually[2].
• Aging population: By 2030, adults aged 60+ are projected to comprise 21% of global populations, increasing demand for inhaled therapies.

Regulatory and Policy Trends

• Generic Expiration & Biosimilars: The expiration of patents for key formulations has led to generic entry, pressuring branded prices.
• Environmental Policies: The shift from chlorofluorocarbon (CFC) inhalers to hydrofluoroalkane (HFA) devices, and recent moves to develop environmentally sustainable inhalers.
• Pricing & Reimbursement: Governments and insurers seeking cost-effective therapies may favor generics, impacting revenue streams.

Technological Innovation

• Inhaler Technology: Shift towards smart inhalers improving adherence and monitoring.
• Formulation Advances: Development of combination therapies (ICS/LABA), which command higher prices and market share.

---

Competitive Landscape

Major Players

Company	Market Share (2022)	Key Products	Patents & Approvals	Notes
Teva Pharmaceuticals	22%	ProAir HFA (Albuterol)	Patented until 2026 (varies)	Generic leader, broad portfolio
AstraZeneca	15%	Pulmicort (Budesonide)	Patented until 2024 (varies)	Innovator with strong pipeline
GlaxoSmithKline (GSK)	12%	Advair/Seretide (ICS/LABA combination)	Patent expired 2019	Focused on combination therapies
Novartis	10%	Ultibro Breezhaler (LABA/LAMA)	Patents pending	Diversifies inhalation portfolio
Others	41%	Various generics and biosimilars	N/A	Entry of biosimilars rising

Patent Topographies and Expiry Dates

Drug/Formulation	Patent Expiry	Impact on Market	Potential for Generic Entry
ProAir HFA (Albuterol inhaler)	2026	Price erosion as generics enter the market	High
Pulmicort (Budesonide DPI)	2024	Increased generic penetration	High
Combination inhalers	2025-2028	Potential for biosimilar competition	Moderate to high

---

Financial Trajectory and Investment Considerations

Revenue Trends and Forecasts

Year	Albuterol Revenue ($ million)	Budesonide Revenue ($ million)	Key Factors
2022	2,400	2,100	Patents intact, high brand loyalty
2025	1,800	2,400	Patent expirations, generic entry
2030	1,200	2,800	Market saturation, biosimilar competition

Investment Risks and Opportunities

Risks	Opportunities
Patent expiries leading to revenue erosion	Development of next-generation inhaler devices
Increased competition from biosimilars	Expansion into emerging markets
Regulatory changes favoring generics	Growth of combination therapy segments
Market consolidation or price controls	Personalized medicine and adherence monitoring technologies

---

Comparison: Albuterol Sulfate vs. Budesonide

Criteria	Albuterol Sulfate	Budesonide
Therapeutic Role	Rescue medication for bronchospasm	Maintenance therapy for airway inflammation
Patent & Exclusivity	Expired or expiring (2019-2026)	Expiring (2024-2027)
Market Maturity	Mature, high penetration	Mature, but with potential for growth via biosimilars
Pricing Dynamics	Price erosion post-patent expiry	Steady; potentially increased with bios Berns
Innovation Trajectory	Focus on inhaler delivery optimization	Focus on combination inhalers and biosimilars

---

Deep Dive: Market Entry and Growth Strategies

Strategy	Description & Rationale	Impacted Segment
Generics & Biosimilars	Accelerates entry post-patent expiry; lowers prices	All
Device Innovation	Smart inhalers, breath-detection sensors to improve adherence	Nascent, premium segments
Combination Inhalers	Improve efficacy and compliance, command premium prices	Long-term control medications
Market Expansion	Penetrate emerging markets with cost-competitive therapies	Developing countries
Partnerships & Collaborations	Co-development, licensing to diversify portfolios	All segments

---

Regulatory Environment & Policy Impact

Region	Key Policies	Impact on Market
United States	FDA approval pathways for generics, biosimilars; Pumping prices for inhalers	Increased generic uptake, downward pressure on revenues
European Union	EMA guidelines, focus on inhaler environmental impact	Accelerating switch to eco-friendly devices
Asia-Pacific	Expanding healthcare coverage; rising disease burden	Accelerated market growth; price sensitivity
Global	WHO initiatives targeting affordability and access	Potential for competitive pricing strategies

---

Deepening Market Outlook: 2023-2030

Aspect	Details
Patent Cliffs	Major patents expiring between 2024-2026, leading to price competition
R&D Investment	Increasing focus on inhaler technology, personalized inhalers, and biosimilars
Market Penetration	Growth prospects strongest in Asia-Pacific and Latin America
Digital Health Integration	Adoption of AI-driven inhaler monitoring to enhance adherence and data collection

---

Key Takeaways

• Patents for key formulations are rapidly expiring, creating significant opportunities for generic and biosimilar entrants, which will pressure pricing but also expand access.
• Market growth remains resilient owing to the rising burden of respiratory diseases, especially in aging and developing populations.
• Innovation in inhaler technology and combination therapies serves as a critical differentiation strategy for industry players.
• Regulatory policies and environmental considerations influence product development, device design, and market entry.
• Investors should evaluate risk profiles related to patent expirations, competitive dynamics, and technological advancements while identifying growth opportunities in emerging markets.

---

FAQs

Q1: What is the primary driver of growth in the albuterol sulfate and budesonide markets?
Increasing global prevalence of asthma and COPD, aging populations, and expanding access in emerging markets.

Q2: How do patent expiries impact the profitability of inhalation drugs?
Patent expiries typically lead to generic entry, causing significant price reductions and revenue declines for branded formulations.

Q3: What technological innovations could alter the market landscape?
Smart inhalers with adherence monitoring, personalized inhaler devices, and development of biosimilars for combination therapies.

Q4: Are there regulatory barriers to entering the generic inhaler market?
Yes, notably quality standards for inhaler devices vary across regions, and approval pathways for generics can be complex.

Q5: Which regions present the most growth potential for these therapies?
Asia-Pacific and Latin America are expected to see the fastest growth due to demographic shifts and increasing healthcare access.

---

References

[1] Grand View Research. "Respiratory Drugs Market Size, Share & Trends Analysis Report." 2023.
[2] World Health Organization. "Chronic respiratory diseases key facts." 2022.